Mezzanine and Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2020

Stockholders' Equity Note [Abstract]

Stock Option Transactions Under Stock Option Plans

The Company’s outstanding stock options consisted of the following:

	Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (in thousands)
Options outstanding at January 1, 2020	607,346	$	9.22	3.42	$	5,600
Options granted	11,742	18.41		—	—
Options exercised	(120,000)	2.58		—	1,800
Options forfeited	(12,228)	17.57		—	—
Options outstanding at June 30, 2020	486,860	$	10.86	3.70	$	2,900
Options exercisable at June 30, 2020	380,894	$	7.11	2.74	$	3,000

Schedule of Stock Options, Valuation Assumptions

During the six months ended June 30, 2020, the Company granted 11,742 stock options with a vesting period of five-years to certain ApolloMed board members with an exercise price of $18.41, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:

June 30, 2020	Board Members
Expected term	3.0 years
Expected volatility	90.01		%
Risk-free interest rate	1.43		%
Market value of common stock	$	10.56
Annual dividend yield	—		%
Forfeiture rate	—		%

Schedule of Outstanding Warrants

The Company’s outstanding warrants consisted of the following:

	Shares	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (in thousands)
Warrants outstanding at January 1, 2020	3,154,590	$	9.96	2.01	$	26,700
Warrants granted	—	—		—	—
Warrants exercised	(273,900)	9.32		—	2,000
Warrants expired/forfeited	—	—		—	—
Warrants outstanding at June 30, 2020	2,880,690	$	10.02	1.61	$	18,700

Exercise Price Per Share		Warrants Outstanding	Weighted Average Remaining Contractual Life	Warrants Exercisable	Weighted Average Exercise Price Per Share
$	9.00	754,870	0.29	754,870	$	9.00
10.00		1,313,345	1.85	1,313,345	10.00
11.00		812,475	2.44	812,475	11.00
$ $ 9.00 –11.00		2,880,690	1.61	2,880,690	$	10.02